|
|
| Line 1: |
Line 1: |
| | | | |
| | ==Crystal structure of human chymotrypsin C (CTRC) bound to inhibitor eglin c from Hirudo medicinalis== | | ==Crystal structure of human chymotrypsin C (CTRC) bound to inhibitor eglin c from Hirudo medicinalis== |
| - | <StructureSection load='4h4f' size='340' side='right' caption='[[4h4f]], [[Resolution|resolution]] 1.90Å' scene=''> | + | <StructureSection load='4h4f' size='340' side='right'caption='[[4h4f]], [[Resolution|resolution]] 1.90Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4h4f]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Hirme Hirme] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4H4F OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4H4F FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4h4f]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Hirudo_medicinalis Hirudo medicinalis] and [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4H4F OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4H4F FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CLCR, CTRC ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4h4f FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4h4f OCA], [https://pdbe.org/4h4f PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4h4f RCSB], [https://www.ebi.ac.uk/pdbsum/4h4f PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4h4f ProSAT]</span></td></tr> |
| - | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Chymotrypsin_C Chymotrypsin C], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.2 3.4.21.2] </span></td></tr>
| + | |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4h4f FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4h4f OCA], [http://pdbe.org/4h4f PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4h4f RCSB], [http://www.ebi.ac.uk/pdbsum/4h4f PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4h4f ProSAT]</span></td></tr> | + | |
| | </table> | | </table> |
| | == Disease == | | == Disease == |
| - | [[http://www.uniprot.org/uniprot/CTRC_HUMAN CTRC_HUMAN]] Hereditary chronic pancreatitis. Note=Genetic variations in CTRC can predispose to chronic pancreatitis by diminishing its protective trypsin-degrading activity. | + | [https://www.uniprot.org/uniprot/CTRC_HUMAN CTRC_HUMAN] Hereditary chronic pancreatitis. Note=Genetic variations in CTRC can predispose to chronic pancreatitis by diminishing its protective trypsin-degrading activity. |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/CTRC_HUMAN CTRC_HUMAN]] Has chymotrypsin-type protease activity and hypocalcemic activity. [[http://www.uniprot.org/uniprot/ICIC_HIRME ICIC_HIRME]] Inhibits both elastase and cathepsin G. | + | [https://www.uniprot.org/uniprot/CTRC_HUMAN CTRC_HUMAN] Has chymotrypsin-type protease activity and hypocalcemic activity. |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 24: |
Line 22: |
| | | | |
| | ==See Also== | | ==See Also== |
| - | *[[Chymotrypsin|Chymotrypsin]] | + | *[[Chymotrypsin 3D structures|Chymotrypsin 3D structures]] |
| | *[[Eglin|Eglin]] | | *[[Eglin|Eglin]] |
| | == References == | | == References == |
| Line 30: |
Line 28: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Chymotrypsin C]] | + | [[Category: Hirudo medicinalis]] |
| - | [[Category: Hirme]] | + | [[Category: Homo sapiens]] |
| - | [[Category: Human]] | + | [[Category: Large Structures]] |
| - | [[Category: Batra, J]] | + | [[Category: Batra J]] |
| - | [[Category: Radisky, E S]] | + | [[Category: Radisky ES]] |
| - | [[Category: Soares, A S]] | + | [[Category: Soares AS]] |
| - | [[Category: Hydrolase-hydrolase inhibitor complex]]
| + | |
| - | [[Category: Protease inhibitor]]
| + | |
| - | [[Category: Serine protease]]
| + | |
| Structural highlights
Disease
CTRC_HUMAN Hereditary chronic pancreatitis. Note=Genetic variations in CTRC can predispose to chronic pancreatitis by diminishing its protective trypsin-degrading activity.
Function
CTRC_HUMAN Has chymotrypsin-type protease activity and hypocalcemic activity.
Publication Abstract from PubMed
Human chymotrypsin C (CTRC) is a pancreatic serine protease that regulates activation and degradation of trypsinogens and procarboxypeptidases by targeting specific cleavage sites within their zymogen precursors. In cleaving these regulatory sites, which are characterized by multiple flanking acidic residues, CTRC shows substrate specificity that is distinct from that of other isoforms of chymotrypsin and elastase. Here, we report the first crystal structure of active CTRC, determined at 1.9-A resolution, revealing the structural basis for binding specificity. The structure shows human CTRC bound to the small protein protease inhibitor eglin c, which binds in a substrate-like manner filling the S6-S5' subsites of the substrate binding cleft. Significant binding affinity derives from burial of preferred hydrophobic residues at the P1, P4, and P2' positions of CTRC, although acidic P2' residues can also be accommodated by formation of an interfacial salt bridge. Acidic residues may also be specifically accommodated in the P6 position. The most unique structural feature of CTRC is a ring of intense positive electrostatic surface potential surrounding the primarily hydrophobic substrate binding site. Our results indicate that long-range electrostatic attraction toward substrates of concentrated negative charge governs substrate discrimination, which explains CTRC selectivity in regulating active digestive enzyme levels.
Long-range Electrostatic Complementarity Governs Substrate Recognition by Human Chymotrypsin C, a Key Regulator of Digestive Enzyme Activation.,Batra J, Szabo A, Caulfield TR, Soares AS, Sahin-Toth M, Radisky ES J Biol Chem. 2013 Apr 5;288(14):9848-59. doi: 10.1074/jbc.M113.457382. Epub 2013 , Feb 19. PMID:23430245[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Batra J, Szabo A, Caulfield TR, Soares AS, Sahin-Toth M, Radisky ES. Long-range Electrostatic Complementarity Governs Substrate Recognition by Human Chymotrypsin C, a Key Regulator of Digestive Enzyme Activation. J Biol Chem. 2013 Apr 5;288(14):9848-59. doi: 10.1074/jbc.M113.457382. Epub 2013 , Feb 19. PMID:23430245 doi:http://dx.doi.org/10.1074/jbc.M113.457382
|
